论文部分内容阅读
用杂交瘤技术制备２株单克隆抗体（单抗）２Ｇ２Ｂ２、２Ｇ２Ｃ２。经研究发现，它们主要与胸腺细胞、脐血及ＰＨＡ激活的外周血单个核细胞等反应；免疫组化显示其主要作用于皮质胸腺细胞；与造血系统中分化早期的瘤细胞、骨髓瘤细胞等反应阳性率较高。生物学特性鉴定结果提示，单抗均属免疫球蛋白ＩｇＧ１亚类，腹水效价达１：１２８０００，所识别抗原分子量为４５／４６ＫＤａ，无抗原调变作用。故２Ｇ２Ｂ２、２Ｇ２Ｃ２是类似ＯＫＴ１０的抗ＣＤ３８单抗，但竞争抑制结果表明三者分别作用于不同的抗原决定簇，即２Ｇ２Ｂ２、２Ｇ２Ｃ２是两个抗ＣＤ３８新单抗。
Two monoclonal antibodies (mAb) 2G2B2 and 2G2C2 were prepared by hybridoma technology. The study found that they mainly with thymocytes, umbilical cord blood and PHA-activated peripheral blood mononuclear cells and other reactions; immunohistochemistry showed that its main role in cortical thymocytes; and hematopoietic system in the early differentiation of tumor cells, myeloma cells The positive reaction rate is high. Biological characteristics of the results suggest that monoclonal antibodies are immunoglobulin IgG1 subclass, ascites titer of 1: 128000, the identified antigen molecular weight 45 / 46KDa, no antigen modulation. Therefore, 2G2B2 and 2G2C2 are anti-CD38 mAbs like OKT10, but competitive inhibition results indicate that the three act on different antigenic determinants, namely 2G2B2 and 2G2C2 are two anti-CD38 monoclonal antibodies.